DMKJ
David M. Knott Jr Portfolio holdings
AUM
$221M
This Quarter Return
+14.16%
1 Year Return
+22.52%
3 Year Return
+148.91%
5 Year Return
–
10 Year Return
–
AUM
$277M
AUM Growth
+$277M
(-2.8%)
Cap. Flow
-$6.89M
Cap. Flow
% of AUM
-2.49%
Top 10 Holdings %
Top 10 Hldgs %
77.48%
Holding
98
New
6
Increased
9
Reduced
11
Closed
9
Top Buys
| 1 |
Janus Henderson AAA CLO ETF
JAAA
|
$25.6M |
| 2 |
Collegium Pharmaceutical
COLL
|
$943K |
| 3 |
Pfizer
PFE
|
$796K |
| 4 |
ATYR
aTyr Pharma
ATYR
|
$727K |
| 5 |
Medtronic
MDT
|
$639K |
Top Sells
| 1 |
Calumet Specialty Products
CLMT
|
$14.8M |
| 2 |
Panagram BBB-B CLO ETF
CLOZ
|
$13.3M |
| 3 |
GSK
GSK
|
$2.66M |
| 4 |
Digimarc
DMRC
|
$2.25M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$1.85M |
Sector Composition
| 1 | Materials | 29.62% |
| 2 | Healthcare | 26.23% |
| 3 | Financials | 16.88% |
| 4 | Communication Services | 7.75% |
| 5 | Industrials | 0.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Calumet Specialty Products
CLMT
$1.41B
| $80.4M | 29.08% |
3,651,361
-673,639
| -16% | -$14.8M |
|
2
Apollo Global Management
APO
$77.9B
| $37.2M | 13.44% |
225,000
| – | – |
|
|
3
Janus Henderson AAA CLO ETF
JAAA
$24.9B
| $29.9M | 10.83% |
590,397
+505,568
| +596% | +$25.6M |
|
4
Alphabet (Google) Class C
GOOG
$2.58T
| $21.4M | 7.73% |
112,220
| – | – |
|
5
DocGo
DCGO
$153M
| $13M | 4.71% |
3,070,850
| – | – |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $7.4M | 2.68% |
159,300
-20,700
| -12% | -$961K |
|
|
7
Pfizer
PFE
$141B
| $6.75M | 2.44% |
254,537
+30,000
| +13% | +$796K |
|
8
Invesco AAA CLO Floating Rate Note ETF
ICLO
$344M
| $5.17M | 1.87% |
201,487
+12,600
| +7% | +$323K |
|
9
JPMorgan Chase
JPM
$829B
| $5.03M | 1.82% |
20,985
| – | – |
|
10
Catalyst Pharmaceutical
CPRX
$2.52B
| $4.38M | 1.58% |
210,000
-2,000
| -0.9% | -$41.7K |
|
11
Travere Therapeutics
TVTX
$1.56B
| $3.97M | 1.44% |
228,000
-30,231
| -12% | -$527K |
|
12
OmniAb
OABI
$230M
| $3.87M | 1.4% |
1,094,505
-54,000
| -5% | -$191K |
|
|
AVDL
13
Avadel Pharmaceuticals
AVDL
$1.43B
| $3.65M | 1.32% |
346,904
+14,904
| +4% | +$157K |
|
14
Xeris Biopharma Holdings
XERS
$1.26B
| $3.39M | 1.23% |
1,000,000
| – | – |
|
15
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.31M | 1.2% |
440,000
+58,000
| +15% | +$436K |
|
16
Ardelyx
ARDX
$1.53B
| $3.1M | 1.12% |
612,270
-70,597
| -10% | -$358K |
|
|
ESGR
17
DELISTED
Enstar Group
ESGR
| $2.42M | 0.87% |
7,500
| – | – |
|
18
Immunovant
IMVT
$2.56B
| $2.28M | 0.82% |
92,000
| – | – |
|
19
CSX Corp
CSX
$60.6B
| $2.26M | 0.82% |
70,000
| – | – |
|
20
Protagonist Therapeutics
PTGX
$3.67B
| $2.02M | 0.73% |
52,368
| – | – |
|
|
INZY
21
DELISTED
Inozyme Pharma
INZY
| $1.93M | 0.7% |
695,000
+130,451
| +23% | +$361K |
|
22
AllianceBernstein
AB
$4.38B
| $1.78M | 0.64% |
48,000
| – | – |
|
23
Syndax Pharmaceuticals
SNDX
$1.41B
| $1.69M | 0.61% |
128,000
+5,856
| +5% | +$77.4K |
|
24
Viking Therapeutics
VKTX
$3.04B
| $1.57M | 0.57% |
39,036
| – | – |
|
|
25
Panagram BBB-B CLO ETF
CLOZ
$846M
| $1.29M | 0.47% |
47,807
-495,061
| -91% | -$13.3M |
|